Viking Therapeutics, Inc. announced positive top-line results from the Phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation for patients with obesity.
The study achieved primary and secondary endpoints, showing statistically significant reductions in body weight with VK2735 compared to placebo.
Participants demonstrated up to a 12.2% mean weight loss after 13 weeks of VK2735 treatment.
Primary and Secondary Endpoints Achieved
VK2735 demonstrated statistically significant reductions in body weight compared to placebo, showing effectiveness in treating obesity.
Safety and Tolerability Confirmed
VK2735 was well-tolerated with low discontinuation rates due to adverse events, indicating promising safety profile.
Exploratory Assessment Success
Low dose maintenance treatment with VK2735 showed positive proof of concept, indicating potential long-term benefits.
Progressive Weight Reduction
Participants saw progressive reductions in body weight with no plateau observed at 13 weeks, highlighting the continued effectiveness of VK2735.
- The Phase 2 trial results provide promising evidence for VK2735's efficacy in treating obesity, a significant health concern globally.
- VK2735 demonstrated substantial weight loss compared to placebo, offering hope for patients struggling with obesity and related comorbidities.
Viking Therapeutics' Phase 2 trial results for VK2735 highlight the drug's effectiveness in reducing body weight and its promising safety profile. These findings are a significant step forward in the development of treatments for metabolic disorders like obesity.